Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 146Breast Neoplasms 143Neoplasms 142Colorectal Neoplasms 135Recurrence 104Ovarian Neoplasms 100Pancreatic Neoplasms 81Lung Neoplasms 81Multiple Myeloma 80Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Lymphoma, B-Cell 53Endometrial Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

Taxes 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Pancreatic Ductal Adenocarcinoma (PDAC) × Clear all
NCT06182072 2025-10-01

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

ProDa BioTech, LLC

Phase 1 Recruiting
46 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡